Crizotinib possessed a lower capacity of ALK inhibition in vitro than other newer generation ALK inhibitors [9, 10] and its concentration at tumour sites may be influenced by the drug transporter P-glycoprotein [11] which is present in a wide range of human tissues including the blood-brain barrier [12], liver and adrenal gland [13]. Here, ALK is linked to neoplasm.